Financial comparisons Cizzle Biotechnology Holdings Plc
Equities
PSL
GB00BNG2VN02
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.550 GBX | 0.00% |
|
0.00% | - |
| 05/11 | Cizzle Biotechnology Raises Funds via Convertible Loan Note Issue | MT |
| 05/11 | Cizzle Biotechnology announces LOI with leading UK clinical diagnostic group | RE |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
| 725.46Cr | 9.67% | 17.9% | 6.77% | 3.48% | 1.5x | ||
| 1.54TCr | 8.91% | 20.12% | 33.53% | 5.12% | 3.33x | ||
| 381.02Cr | -16.92% | -14.91% | -18.77% | -11% | 4.06x | ||
| 240.81Cr | 11.88% | 13.83% | 2.46% | 2.14% | 1.28x | ||
| 210.91Cr | 19.17% | 21.38% | 58.42% | 21.52% | -1.39x | ||
| 719.64Cr | 5.84% | 14.63% | 7.8% | 3.73% | 1.93x | ||
| 828.17Cr | 9.56% | 19.29% | 12.39% | 6.87% | 1.66x | ||
| 38Cr | -103.97% | -76.66% | - | -37.71% | -1.14x | ||
| 70Cr | -64.4% | -67.38% | -93.12% | -15.15% | 2.26x | ||
| 69Cr | -107.63% | -20.47% | - | -25.37% | 0.13x | ||
| 405Cr | 0.25% | 19.9% | 15.1% | 6.78% | 2.05x | ||
| 121.96Cr | 6.02% | 31.45% | 15.37% | 11.65% | 0.43x | ||
| 197.82Cr | 4.23% | 28.66% | 13.31% | 8.32% | 0.34x | ||
| 1.29Cr | -1,409.6% | -1,383.2% | -148.95% | - | 0.4x | ||
| 51Cr | -13.19% | -41.67% | -31.26% | -21.6% | -0.14x | ||
| 168.18Cr | 14.61% | 17.14% | 13.7% | 7.12% | 1.33x | ||
| 85.53L | -2,137.48% | -2,340.29% | -70.98% | -64.03% | 1.96x | ||
| Average | 339.41Cr | -221.36% | -220.02% | -12.28% | -6.13% | 1.18x | |
| Weighted average by Cap. | 511.69Cr | -108.3% | -102.46% | -1.95% | -2.75% | 1.64x |
- Stock Market
- Equities
- PSL Stock
- Sector Cizzle Biotechnology Holdings Plc
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















